Recent Finacing
Recent Raise
George Medicines develops single‑pill fixed‑dose combination therapies for noncommunicable diseases, advancing GMRx2 (Phase III triple combo for hypertension) and GMRx4 (Phase II ultra‑low‑dose triple for type 2 diabetes).